Pipeline VP-102

Verricaʼs lead product candidate, VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. We are developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, two of the most common viral skin diseases in medical dermatology.

Initial Phase 3 in 2H 2024**
Evaluate potential second Phase 2 trial***

*Originally designed Phase 2 program completed.
**Timing of clinical trials for External Genital Warts may be subject to change.
***Company evaluating potential for conducting an additional Phase 2 trial based on FDA feedback for Phase 3 protocol.

We retain exclusive royalty-free rights to YCANTH (VP-102) across all indications globally

Common Warts
Common warts (verruca vulgaris) are contagious skin growths caused by a human papilloma virus (HPV). They represent one of the largest unmet needs in dermatology, with approximately 22 million cases in the United States. There are no FDA-approved treatments for common warts, which can be difficult to treat and negatively affect quality of life. Verrica has announced positive top-line results from its COVE-1 Phase 2 open-label clinical study of VP-102 for the treatment of common warts.

External Genital Warts
External genital warts are a viral skin disease caused by a human papilloma virus (HPV), which forms lesions on the surface of the skin on or near the genitals. HPV is the most common sexually transmitted infection in the United States. Verrica has announced positive top-line results from its CARE-1 Phase 2 study and intends to conduct additional studies of VP-102 for the treatment of external genital warts.


Verrica Receives Permanent J‑Code for YCANTH™